Search results
Added:
6 months ago
Added:
2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients.
Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin…
View more
Added:
2 years ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The…
View more
Added:
2 weeks ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more
Added:
1 year ago
Added:
10 months ago
Radcliffe Medical Education, is proud to bring to you this roundtable series which is designed to equip healthcare professionals with the knowledge and tools necessary to identify high-risk patients indicative of worsening HF and to implement effective management strategies. Watch Dr Javed Butler (Baylor Scott & White Health, Dallas, US); Dr Shelley Zieroth (University of Manitoba, Winnipeg, CA)…
View more
Added:
1 year ago
AHA 2023 — Investigator Dr Dike Bevis Ojji (University of Abuja, NG) talks with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) about the Hypertension Treatment in Nigeria Program (NCT04158154).The aim of this study (Washington University School of Medicine) and employing an interrupted time series design, is to assess the implementation and evaluation of a culturally- and…
View more
Added:
2 weeks ago
ADA 2025 - Final results from the CATALYST trial show mifepristone significantly improved glucose control in patients with hypercortisolism and difficult-to-control diabetes.We are joined by Dr John Buse (University of North Carolina, Chapel Hill, US) to discuss phase 4 results from CATALYST (NCT05772169), a randomised, placebo-controlled, multi-center trial investigating the safety and efficacy…
View more
Added:
1 year ago
Added:
2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more